Contact
searchSearch
HMP Global
Headshot of Shebli Atrash, Levine Cancer Institute, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Study Finds Unequal Access to Care for Black Patients With Multiple Myeloma
12/29/2021
Maria Asimopoulos; Samantha Matthews
Shebli Atrash, MD, physician, plasma cell disorder team, Levine Cancer Institute, North Carolina, highlights findings presented at the 63rd ASH Annual Meeting & Exposition that indicated racial discrepancies in patients’ access to timely...
Shebli Atrash, MD, physician, plasma cell disorder team, Levine Cancer Institute, North Carolina, highlights findings presented at the 63rd ASH Annual Meeting & Exposition that indicated racial discrepancies in patients’ access to timely...
Shebli Atrash, MD, physician,...
12/29/2021
First Report Managed Care
Conference Coverage
Examining Treatment Patterns, Outcomes of Patients With CLL Treated With First-line Therapy
12/29/2021
Maria Asimopoulos
"Clinical outcomes were improved in patients receiving novel targeted oral agents, both overall and in high-risk subgroups," stated researchers at the 63rd ASH Annual Meeting & Exposition.
"Clinical outcomes were improved in patients receiving novel targeted oral agents, both overall and in high-risk subgroups," stated researchers at the 63rd ASH Annual Meeting & Exposition.
"Clinical outcomes were improved...
12/29/2021
First Report Managed Care
Conference Coverage
High Response Rates Associated With Combo Daratumumab, Bortezomib, and Dexamethasone Therapy for R/R MM
12/29/2021
Maria Asimopoulos
Recent data shows good tolerability and high response rates after first relapse for patients with relapsed/refractory multiple myeloma treated with daratumumab, bortezomib, and dexamethasone.
Recent data shows good tolerability and high response rates after first relapse for patients with relapsed/refractory multiple myeloma treated with daratumumab, bortezomib, and dexamethasone.
Recent data shows good...
12/29/2021
First Report Managed Care
Conference Coverage
Long-term Follow Up of Combo Ibrutinib, Venetoclax as CLL Therapy for High-risk Patients
12/28/2021
Samantha Matthews
Study authors presented the latest data from a phase 2 trial examining patients with chronic lymphocytic leukemia treated with combination ibrutinib and venetoclax, with a particular focus on minimal residual disease assessment.
Study authors presented the latest data from a phase 2 trial examining patients with chronic lymphocytic leukemia treated with combination ibrutinib and venetoclax, with a particular focus on minimal residual disease assessment.
Study authors presented the...
12/28/2021
First Report Managed Care
Conference Coverage
Measuring Costs, Utilization Correlated With Hospital-based Care for Patients With Non-Hodgkin's Lymphoma Subtypes
12/28/2021
Samantha Matthews
"Given the increased availability of effective oral therapeutics, optimal and timely disease control in the outpatients setting can potentially prevent or decrease hospitalizations and reduce economic burden on health care," said study...
"Given the increased availability of effective oral therapeutics, optimal and timely disease control in the outpatients setting can potentially prevent or decrease hospitalizations and reduce economic burden on health care," said study...
"Given the increased...
12/28/2021
First Report Managed Care
Conference Coverage
Ibrutinib Monotherapy Induced Durable Remission Rates Compared With Combo Therapy
12/28/2021
Samantha Matthews
Researchers at the 63rd ASH Annual Meeting & Exposition reported the long-term outcomes for patients with CLL and TP53 aberrations who were treated with either ibrutinib alone or combo ibrutinib plus rituximab.
Researchers at the 63rd ASH Annual Meeting & Exposition reported the long-term outcomes for patients with CLL and TP53 aberrations who were treated with either ibrutinib alone or combo ibrutinib plus rituximab.
Researchers at the 63rd ASH...
12/28/2021
First Report Managed Care
Conference Coverage
Isatuximab Shows Promise With Early Real-World Efficacy, Tolerability Data
12/14/2021
Edan Stanley
Initial real-world data offers encouraging results on the efficacy and tolerability of isatuximab with pomalidomide and dexamethasone for patients with relapsed/refractory multiple myeloma, according to a poster presentation at the 63rd ASH...
Initial real-world data offers encouraging results on the efficacy and tolerability of isatuximab with pomalidomide and dexamethasone for patients with relapsed/refractory multiple myeloma, according to a poster presentation at the 63rd ASH...
Initial real-world data offers...
12/14/2021
First Report Managed Care
Conference Coverage
Sustained Health-related Quality of Life Improvement Associated With Daratumumab for Patients With Multiple Myeloma
12/14/2021
Edan Stanley
According to data presented at the 63rd ASH Annual Meeting & Exposition, updated patient-reported outcomes show sustained and clinically meaningful improvements for patients with multiple myeloma treated with daratumumab.
According to data presented at the 63rd ASH Annual Meeting & Exposition, updated patient-reported outcomes show sustained and clinically meaningful improvements for patients with multiple myeloma treated with daratumumab.
According to data presented at...
12/14/2021
First Report Managed Care

Hematologists from around the world share the latest news, insights, and findings on malignant and nonmalignant blood diseases and conditions.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use